SYDNEY - ( BUSINESS WIRE ) - Australian clinical-stage drug development company Noxopharm (ASX: NOX) has released the first preliminary data from its phase I clinical trial NOXCOVID, which assesses the suitability of idronoxil ( Veyonda ® ), a TBK1 (TANK-binding kinase 1) inhibitor, as an anti-inflammatory in patients with a moderate form of COVID-19. Based on the first positive results, Noxopharm has initiated discussions to integrate Veyonda into one of the global clinical trial programs aimed at identifying effective anti-inflammatory treatments for COVID-19.
SYDNEY--(BUSINESS WIRE)--Noxopharm, a clinical-stage Australian oncology drug development company listed on the ASX (ASX:NOX), has claimed a breakthrough in the search for restoring immune function within “cold” microtumors, converting them to so-called “hot” tumors.
Noxopharm (NOX:ASX) announces today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for Veyonda® for combination treatment with doxorubicin in patients with soft tissue sarcomas.